Literature DB >> 10866129

Induction of Fas ligand-mediated apoptosis by interferon-alpha.

K A Kirou1, R K Vakkalanka, M J Butler, M K Crow.   

Abstract

Interferon-alpha (IFN-alpha) was among the first cytokines studied and the earliest to be used in clinical medicine for the treatment of viral infections and malignancies. Although the capacity of IFN-alpha to augment NK cell cytotoxicity against virus-infected target cells or tumor cells is well established, the mechanism has not been fully elucidated. Here we report that IFN-alpha stimulation of PBMC from healthy donors induces Fas (CD95) ligand (FasL) transcription and leads to increased cell surface FasL expression exclusively on the NK cell fraction. Furthermore, IFN-alpha augments the FasL-mediated cytotoxicity of normal PBMC against Fas-sensitive lymphoid tumor cells. In the context of innate immunity, induction of FasL by IFN-alpha can be viewed as an efficient mechanism to potentiate NK cell cytotoxicity in the presence of harmful targets, such as virally infected or transformed cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866129     DOI: 10.1006/clim.2000.4866

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  10 in total

1.  Antiviral treatment with alpha interferon up-regulates CD14 on liver macrophages and its soluble form in patients with chronic hepatitis B.

Authors:  Patrizia Carotenuto; Debby van Riel; André Artsen; Sven Bruijns; Fons G Uytdehaag; Jon D Laman; Andeltje B van Nunen; Pieter E Zondervan; Robert A De Man; Albert D Osterhaus; Oscar Pontesilli
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

2.  Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

Authors:  Adrianos Nezos; Fotini Gravani; Anna Tassidou; Efstathia K Kapsogeorgou; Michael Voulgarelis; Michael Koutsilieris; Mary K Crow; Clio P Mavragani
Journal:  J Autoimmun       Date:  2015-07-14       Impact factor: 7.094

3.  The anti-angiogenic activity of IL-12 is increased in iNOS-/- mice and involves NK cells.

Authors:  Aleksandra Bielawska-Pohl; Séverine Blesson; Houssem Benlalam; Aurélie Trenado; Paule Opolon; Olivia Bawa; Valérie Rouffiac; Danuta Dus; Claudine Kieda; Salem Chouaib
Journal:  J Mol Med (Berl)       Date:  2010-04-11       Impact factor: 4.599

4.  Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients.

Authors:  E Stylianou; A Yndestad; L I Sikkeland; V Bjerkeli; J K Damås; T Haug; H G Eiken; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

5.  Innate immune functions of microglia isolated from human glioma patients.

Authors:  S Farzana Hussain; David Yang; Dima Suki; Elizabeth Grimm; Amy B Heimberger
Journal:  J Transl Med       Date:  2006-03-30       Impact factor: 5.531

6.  Systemic lupus erythematosus and the type I interferon system.

Authors:  Lars Rönnblom; Gunnar V Alm
Journal:  Arthritis Res Ther       Date:  2003-01-20       Impact factor: 5.156

Review 7.  Global virus outbreaks: Interferons as 1st responders.

Authors:  Ben X Wang; Eleanor N Fish
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

Review 8.  Toll-like Receptors from the Perspective of Cancer Treatment.

Authors:  Nasir Javaid; Sangdun Choi
Journal:  Cancers (Basel)       Date:  2020-01-27       Impact factor: 6.639

Review 9.  Microarray analysis of gene expression in lupus.

Authors:  Mary K Crow; Jay Wohlgemuth
Journal:  Arthritis Res Ther       Date:  2003-10-13       Impact factor: 5.156

10.  Bioinformatics analysis of the factors controlling type I IFN gene expression in autoimmune disease and virus-induced immunity.

Authors:  Di Feng; Betsy J Barnes
Journal:  Front Immunol       Date:  2013-09-19       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.